AI Summary
This article discusses a study on enobosarm, a selective androgen receptor modulator, in the treatment of advanced breast cancer. The study found that enobosarm has anti-tumor activity in patients with estrogen receptor-positive and HER2-negative breast cancer, demonstrating the potential for androgen receptor activation as a treatment strategy. These findings support further clinical investigation of selective androgen receptor activation for the treatment of this specific subtype of breast cancer.
Enobosarm has anti-tumour activity in patients with ER-positive, HER2-negative advanced breast cancer, showing that AR activation can result in clinical benefit, supporting further clinical investigation of selective AR activation strategies for the treatment of AR-positive, ER-positive, HER2-negative advanced breast cancer.